{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["St Thomas N"],"funding":["NCI NIH HHS","NIH HHS"],"pagination":["76"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11763779"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Cutaneous T-cell lymphoma (CTCL) is a rare T-cell malignancy characterized by inflamed and painful rash-like skin lesions that may affect large portions of the body's surface. Patients experience recurrent infections due to a compromised skin barrier and generalized immunodeficiency resulting from a dominant Th2 immune phenotype of CTCL cells. Given the role of the unfolded protein response (UPR) in normal and malignant T-cell development, we investigated the impact of UPR-inducing drugs on the viability, transcriptional networks, and Th2 phenotype of CTCL. We found that CTCL cells were >5-fold more sensitive to the proteasome inhibitor bortezomib (Btz) and exhibited a distinct signaling and transcriptional response compared to normal CD4+ cells. The CTCL response was dominated by the indu"],"journal":["Biomolecules"],"pubmed_title":["Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma."],"pmcid":["PMC11763779"],"funding_grant_id":["R01 CA245081","R01CA245081"],"pubmed_authors":["Reyes L","Golick L","Dolloff NG","Christopher BN","Robinson RM","Chapman E","Zhu X","St Thomas N"],"additional_accession":[]},"is_claimable":false,"name":"Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.","description":"Cutaneous T-cell lymphoma (CTCL) is a rare T-cell malignancy characterized by inflamed and painful rash-like skin lesions that may affect large portions of the body's surface. Patients experience recurrent infections due to a compromised skin barrier and generalized immunodeficiency resulting from a dominant Th2 immune phenotype of CTCL cells. Given the role of the unfolded protein response (UPR) in normal and malignant T-cell development, we investigated the impact of UPR-inducing drugs on the viability, transcriptional networks, and Th2 phenotype of CTCL. We found that CTCL cells were >5-fold more sensitive to the proteasome inhibitor bortezomib (Btz) and exhibited a distinct signaling and transcriptional response compared to normal CD4+ cells. The CTCL response was dominated by the indu","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-18T14:27:55.377Z","creation":"2025-04-07T00:38:39.242Z"},"accession":"S-EPMC11763779","cross_references":{"pubmed":["39858470"],"doi":["10.3390/biom15010076"]}}